Astrazeneca Receives Japan Approval for CFC-free Corticosteroid Inhaler for Paediatric Asthma.Tokyo, Japan, Aug 3, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Astrazeneca announced on July 27 that it had received approval for its Pulmicort Turbuhaler, an inhaler inhaler /in·hal·er/ (in-hal´er) 1. an apparatus for administering vapor or volatilized medications by inhalation. 2. ventilator (2). in·hal·er n. for pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. asthma infants from 6 months to under 5 years old, frrom the Japanese Ministry of Health, Labor and Welfare. Pulmicort Turbuhaler is taken once daily with an electronic nebuliser that change liquid medicines into a fine mist for easy breathing in. The three main efficiency of the drug include reduced inflammation in the airways of lungs, reduced asthma attack frequency by 50% for 2 weeks use and as much as 75% during a 12 week period, and reduced sleep distraction of 61.4%. The drug has been recommended in the guidelines for Management of treatment for Pediatric Patients of Bronchial Asthma bronchial asthma n. A condition of the lungs characterized by widespread narrowing of the airways due to spasm of the smooth muscle, edema of the mucosa, and the presence of mucus in the lumen of the bronchi and bronchioles. , set forth by the Japanese Society of Pediatric Allergy and Clinical Immunology. AstraZeneca expect rapid use of the medication. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion